• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
188664 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  ; ?4 W- ]: n8 S( \2 O5 I) j1 [9 R+ t

% d3 J8 g* K( e9 R  K
  j' x9 j$ g2 p  k0 z( [& }4 W4 ]6 GSub-category:
+ e/ C7 m8 w5 I% h' aMolecular Targets
( }8 m! z! c3 ]) h8 l5 \
! u. D. K' N- |
" t, C% F: g; o) O/ b. X4 MCategory:- B, {+ j0 A" O' C) e
Tumor Biology 2 ~" b8 k4 o1 q9 l( I9 v

0 [/ G9 }2 v! S# x5 @' {! b; U+ Y$ u- |' T5 }8 U" Z/ k
Meeting:
) M9 Z7 {! ]3 {- w% ^2011 ASCO Annual Meeting 7 A. J" Z- z1 n$ T

* l' ~) B% B% ^) Y
4 f% p- Y1 V. w0 t6 YSession Type and Session Title:
# H5 J$ Q- p/ O% r% |Poster Discussion Session, Tumor Biology
: M; O# g1 Y2 u2 l
7 g8 E- g% O8 W% b$ I5 H$ z4 h% `# T9 H7 I& \9 H  s
Abstract No:
' N$ S: I8 @) \7 ^5 h% a10517 / K4 r" ^6 ]0 x) o
; a" l+ D2 k: {/ `
# v3 I3 K( h3 p2 K9 x, A
Citation:
, o: x3 J4 u6 J7 E. m% n. W, tJ Clin Oncol 29: 2011 (suppl; abstr 10517) 2 x8 H" r3 h* P6 x) N

5 }$ a, H5 {- |6 h$ ]5 R* w' T, P/ |. h7 G5 D5 F
Author(s):
; S2 g6 G  \* ~J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
* b! Y; P6 K- V4 T* W% T
- ?; q6 Q! k4 y' ?+ Q
  t9 l8 P3 |: N; {9 s* t( [4 S( {  W- s9 h+ o- o
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.) s/ ^, O7 m0 G! b2 Y

& y( ^1 k& b& o6 f, ~Abstract Disclosures( D6 L% d4 s3 b0 q
" c5 U; z4 ]3 M4 z: Z' d' h
Abstract:
1 e0 c' V5 W/ ^
8 I- K" ^8 N4 U
" L2 H0 E" [$ a1 U" y* l4 A- UBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.# c) f" D, G! U: y3 C- Y6 m
0 O% ]9 n* S4 B# f0 t
# F0 r$ F2 c2 N' `0 Q$ y
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 9 y$ {; L) n5 R, T1 X8 o
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
* A. D5 Y. B- g" i$ h
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 ( c* c6 [+ Z$ Q2 _
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。% d$ E* j0 d% t' E% P
ALK一个指标医院要900多 ...
+ f7 }- Q6 X- _/ P5 H5 E8 Y3 ~
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?9 {6 w+ y0 J/ K8 W0 K

- R+ ?" q! c2 h( w+ c% }4 J现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表